Home
HelpTest ID NBLD0714 Programmed Death-Ligand 1 (PD-L1) (22C3), Semi-Quantitative Immunohistochemistry, Manual
Useful For
Identification of neoplasms expressing programmed cell death 1-ligand 1 (clone 22C3)
Specimen Type
SpecialOrdering Guidance
In patients with specific tumor types, programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is indicated to predict response to treatment with PD-L1 inhibitors. The specific PD-L1 clone, scoring method, and eligibility requirements depend on the tumor type, stage of malignancy, previous treatment outcomes, and specific PD-L1 inhibitor under consideration. For assistance with PD-L1 test selection as well as answers to frequently asked questions, see PD-L1 Immunohistochemistry Testing on MayoClinicLabs.com.
Shipping Instructions
Attach the green pathology address label included in the kit to the outside of the transport container.
Necessary Information
A pathology/diagnostic report and a brief history, including primary site of neoplasm, are required.
Specimen Required
Specimen Type: Tissue
Supplies: Pathology Packaging Kit (T554)
Collection Instructions: Formalin-fixed, paraffin-embedded tissue block; or 3 unstained glass, "positively charged" slides with 4-microns formalin-fixed, paraffin-embedded tissue
Additional Information: One slide will be stained with hematoxylin and eosin and returned.
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Special | Ambient (preferred) | |
| Refrigerated | ||
Reject Due To
| Decalcified bone Wet/frozen tissue Cytology smears Nonformalin fixed tissue including alcohol-formalin-acetic acid (AFA), 95% ethanol, PREFER fixatives or Zinc formalin Nonparaffin embedded tissue Noncharged slides ProbeOn slides |
Reject |
Day(s) Performed
Monday through Friday
Report Available
5 to 7 daysMethod Name
Immunohistochemistry (IHC)
Reporting Name
PD-L1 (22C3) SemiQuant IHC, ManualPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Secondary ID
603762CPT Code Information
88360
Test Classification
This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.Forms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763)
Oncology Test Request (T729)
SANFORD LABORATORY INTERFACE BUILD INFORMATION
| Result Code | Result Code Description |
|---|---|
| 28635 | Interpretation |
| 28636 | Participated In The Interpretation |
| 28637 | Report Electronically Signed By |
| 28638 | Material Received |
| 28639 | Disclaimer |
| 28640 | Case Number |